Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingFME.XETRA
FME.XETRA▲
Fresenius Medical Care Q2 operating income rises 23% at constant currency
Fresenius Medical Care reported a 23% increase in operating income at constant currency for the second quarter of 2026, driven by strong performance in Care Delivery and value-based care. Organic group revenue grew 5%, supported by all three operating segments, while the operating margin expanded by 180 basis points. The company completed its initial EUR 1 billion share buyback program and launched a second EUR 1 billion program, maintaining a net leverage ratio of 2.6x. U.S. same-market treatment growth declined 0.9% due to an operational miss in capturing referrals, prompting an organizational change and a revised full-year expectation around the Q2 level. The 5008X hemodialysis machine rollout accelerated, with 227 clinics converted across 23 states, representing 10% of the company's U.S. machine base. Full-year guidance was confirmed, with operating income expected to remain at a consistently elevated level and a mid-single-digit percentage change range.
Fresenius Medical Care targets ~20% 5008X conversion in 2026 while keeping operating income guidance at mid-single-digit % change
Fresenius Medical Care is targeting around 20% conversion of its machines to the 5008X system in its own clinics by 2026, while confirming its full-year outlook for broadly flat revenue and operating income change in the mid-single-digit percentage range. CEO Helen Giza said the company had converted 227 clinics across 23 states by late July, representing 10% of its machine base, and remains on track for the 2026 target. The company reported a 23% increase in operating income at constant currency in the second quarter, with FME25+ delivering EUR 67 million of sustainable savings. However, U.S. same market treatment growth declined by 0.9%, which Giza attributed to an internal operational miss in capturing referrals, and the company now expects U.S. same market treatment growth in 2026 to remain around the second-quarter level. The full-year TDAPA headwind is now expected to be around EUR 50 million, down from the previously anticipated EUR 100 million, while special items of negative EUR 103 million were recorded in the quarter, mainly related to the TAVNEOS marketing authorization revocation.
Fresenius Medical Care appoints Cassie McLean as Management Board member for Care Delivery
Fresenius Medical Care has appointed Cassie McLean as a member of its Management Board and Chief Executive Officer of the Care Delivery operating segment, effective August 1, 2026. She succeeds Craig Cordola in the role, which has been reshaped to create more direct accountability for operational execution and business performance. McLean joined the company in August 2025 as President of Fresenius Kidney Care and will now assume direct accountability for the global clinic business, including Fresenius Kidney Care in the U.S. and Care Delivery International. Chairman Michael Sen cited her deep dialysis expertise and strong leadership, while CEO Helen Giza noted her rapid improvements in operational visibility and talent strengthening in the U.S. clinic business. McLean previously served as CEO of Monte Nido and spent nearly 16 years at DaVita Kidney Care.
Fresenius Medical Care introduces TherapyWise analytics for kidney replacement therapy
Fresenius Medical Care has introduced TherapyWise, a cloud-based analytics capability available within its NxView 4.0 software platform for the NxStage System One in the United States. TherapyWise provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings by aggregating existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability. The platform consolidates data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods. It securely transmits data from the NxStage System One with NxView to a cloud-based platform, displaying program-level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended for retrospective review and program oversight, not for real-time, patient-specific clinical decision-making.
Peritoneal Dialysis Market Projected to Reach US$ 21.55 Billion by 2034
The global peritoneal dialysis market is forecast to grow from US$ 11.56 billion in 2025 to US$ 21.55 billion by 2034, a compound annual growth rate of 7.4 percent, according to a new report by The Insight Partners. North America leads the market, supported by advanced renal care infrastructure and established reimbursement frameworks, while Asia Pacific is expected to offer strong growth potential due to rising chronic kidney disease volumes and expanding healthcare infrastructure. The product segment dominates by offerings, driven by recurring demand for dialysate solutions, bags, catheters, and cyclers, and automated peritoneal dialysis is the fastest-growing dialysis type as patients prefer overnight treatment and remote monitoring. Homecare settings are becoming increasingly important as healthcare systems promote home dialysis to ease in-center capacity constraints, with Vantive reporting that approximately 4 million people worldwide receive dialysis for chronic kidney disease. Recent industry developments include Fresenius Medical Care’s global launch of the Kinexus digital platform in June 2026 and Vantive’s introduction of the HomeAdvantage home therapy ecosystem in November 2025.
EMA Committee Recommends Revoking TAVNEOS Marketing Authorisation in EU
The European Medicines Agency committee has recommended revoking the EU marketing authorisation for TAVNEOS, affecting Fresenius Medical Care's treatment portfolio for patients in the European Union. The recommendation introduces uncertainty for clinicians and patients relying on this therapy within the EU. Fresenius Medical Care is a global provider of dialysis products and services, so any change in its therapy portfolio can matter for both its operations and patient care. The key question is how the company responds in terms of alternative treatment pathways, clinical guidance, and product planning in Europe.
CHMP recommends revoking EU marketing authorisation for TAVNEOS
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended revoking the European Union marketing authorisation for TAVNEOS, a treatment for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. The recommendation follows an Article 20 non-pharmacovigilance procedure initiated due to concerns related to data handling in the pivotal Phase 3 ADVOCATE trial. The opinion has been sent to the European Commission, and a final decision is expected shortly; if confirmed, TAVNEOS will no longer be authorised in the EU. No new patients will be treated with TAVNEOS in the EU and European Economic Area, and current patients are advised to consult their physician. Vifor Fresenius Medical Care Renal Pharma and CSL, which commercialise TAVNEOS outside the US under a license from ChemoCentryx, stated they will respect the regulatory outcome and are working to ensure a compliant treatment transition.
Vifor Fresenius Medical Care Renal Pharma and CSL·61dRead more ▾
FME.XETRA▼impact 4
Fresenius Medical Care dips after US proposes lower dialysis reimbursement rate
Fresenius Medical Care shares fell about 5% Thursday after the US health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system. CMS proposed a 1.1% increase to the base rate for its end-stage renal disease bundle payment, roughly half what investors had anticipated and well below increases seen in prior years. The regulator also proposed including phosphate binders in the bundle from 2027, removing a payment mechanism that had driven strong uptake of Fresenius's Velphoro drug. UBS analysts said the proposal was worse than usual and below the roughly 2% rate investors had been expecting, warning that they would expect lower utilisation of Velphoro under the bundled payment, meaning the profit pool could fall significantly for Fresenius Medical Care in 2027. While the final rate could still be revised upward, UBS noted that even with such an adjustment, the outcome would likely still imply a margin drag for Medicare patients.
DaVita Outperforms Fresenius Medical Care as Earnings Outlook Diverges
DaVita Inc. has significantly outperformed Fresenius Medical Care AG in recent stock performance and earnings expectations, with DaVita gaining 49.7% over the past year while Fresenius Medical Care declined 14.6%. The Zacks Consensus Estimate for DaVita's 2026 earnings per share suggests a 39.8% improvement from 2025, whereas Fresenius Medical Care's 2026 EPS is expected to decline 7.4%. DaVita currently holds a Zacks Rank #1 (Strong Buy), while Fresenius Medical Care carries a Zacks Rank #5 (Strong Sell). Both stocks trade below their historical valuation levels and at discounts to the broader medical sector, but DaVita's stronger earnings trajectory and improving operating performance make it the more attractive choice at current levels.